A subset of regulatory CD8⁺ T cells slowed atherosclerosis and helped stabilize plaques in mouse models by restoring Notch signaling in vascular smooth muscle cells, according to a study published in Circulation Research. The work also used single-cell RNA sequencing from human atherosclerotic plaques to map how immune cells communicate with vascular cells, but the treatment strategy itself has not been tested in people.
Atherosclerosis is not just a cholesterol storage disease
Atherosclerosis develops when lipids, immune cells and vascular cells accumulate and interact within the arterial wall. Over time, plaques can narrow arteries or become unstable and rupture, triggering a blood clot that may cause a heart attack or stroke.
Cholesterol remains central to the process, but inflammation and immune signaling also help determine whether a plaque progresses, stabilizes or becomes dangerous.
That broader biology helps explain why two people with similar cholesterol levels can have very different plaque burdens and why treatments that lower inflammation can reduce cardiovascular events in selected patients.
Bites of Bio recently covered a study showing that silent atherosclerosis can already be detected in some adults under 30. The new work addresses a different question: how specific immune cells influence the behavior of the vessel wall once atherosclerosis is underway.
The study focused on CD8⁺ T cells and vascular smooth muscle cells
CD8⁺ T cells are best known for killing virus-infected cells and cancer cells. They are also abundant in advanced atherosclerotic plaques, but their role is complicated because not all CD8⁺ T cells behave the same way.
The researchers distinguished between conventional effector CD8⁺ T cells, which can promote inflammation, and a regulatory subset called CD8⁺ Tregs that can suppress excessive immune activation.
The other key cell type in the study was the vascular smooth muscle cell, or VSMC. These cells normally form much of the muscular middle layer of an artery and help regulate vessel tone and structure.
During atherosclerosis, however, VSMCs can switch from a contractile, relatively quiescent state into a synthetic state. They may proliferate, migrate and even adopt macrophage-like features. That plasticity can influence plaque growth and stability.
Human plaque data pointed to CD8⁺ T cells as major immune partners of vascular cells
The team first analyzed single-cell RNA-sequencing datasets from human atherosclerotic plaques and reconstructed cell-to-cell communication networks.
CD8⁺ T cells emerged as one of the immune populations most frequently interacting with vascular smooth muscle cells. The analysis highlighted CD8α as an important component of that communication.
This human dataset did not prove that the cells were causing disease, but it helped the researchers identify the immune-vascular interaction they then tested experimentally.
Effector CD8⁺ T cells disrupted a pathway that keeps smooth muscle cells quiet
The experiments pointed to the Notch signaling pathway as a central part of the mechanism.
Notch is a cell-to-cell communication system that helps regulate cell identity, differentiation and tissue maintenance. In vascular smooth muscle cells, the pathway helps preserve a stable, quiescent phenotype.
In the atherosclerosis models, effector CD8⁺ T cells suppressed VSMC Notch signaling. When that pathway was inhibited, the smooth muscle cells proliferated abnormally and underwent phenotypic switching.
Those changes favored a more disease-promoting state.
Protective CD8⁺ Tregs restored Notch signaling
The regulatory CD8⁺ T cells behaved differently.
These cells expressed higher levels of Notch ligands than conventional CD8⁺ T cells and helped restore Notch signaling in vascular smooth muscle cells.
That signaling activated the Notch-RBPJ-Hes1 pathway. Downstream, Hes1 suppressed genes including Klf4 and Rel, which are involved in smooth muscle cell phenotypic switching and inflammatory behavior.
The effect depended on direct signaling between the regulatory T cells and the vascular cells. When the researchers blocked key Notch ligand-receptor interactions, the protective effect of the CD8⁺ Tregs was lost.
A high-cholesterol environment reduced the protective T-cell population
The study also found that the protective CD8⁺ regulatory T-cell population declined in the setting of a high-cholesterol diet.
That observation fits a broader pattern in atherosclerosis: the metabolic environment does not simply deposit cholesterol in the artery wall. It also changes immune-cell behavior.
As protective immune regulation weakens and pro-inflammatory signaling becomes more dominant, vascular smooth muscle cells may be pushed further away from a stable state.
Transferring protective T cells slowed disease in mice
To test whether the regulatory cells could alter disease progression, the researchers transferred CD8⁺ T-cell populations into atherosclerotic mice.
Adoptive transfer of the protective CD8⁺ Treg population slowed atherosclerosis progression.
Conversely, experiments that interfered with the Notch pathway reduced or eliminated that protection, reinforcing the idea that the benefit depended on immune-to-vascular Notch signaling rather than a nonspecific anti-inflammatory effect.
An antibody shifted the balance toward protective CD8⁺ T cells
The researchers then tested a more drug-like strategy.
They used a non-lytic anti-CD8α antibody. Unlike a depleting antibody, this approach was designed to inhibit harmful CD8⁺ T-cell activation without simply wiping out the entire CD8⁺ T-cell population, which is important for immune defense against infections and cancer.
The treatment expanded the protective CD8⁺ Treg population in atherosclerotic mice.
Compared with untreated disease models, the antibody-treated mice had significantly less plaque area and lipid content and more collagen within plaques.
More collagen in the fibrous cap is generally associated with a more stable plaque phenotype, although plaque stability in mice does not map perfectly onto the risk of plaque rupture in people.
The study targets plaque biology rather than cholesterol itself
The proposed strategy is conceptually different from statins, PCSK9 inhibitors and other lipid-lowering therapies.
Those drugs primarily reduce the amount of atherogenic cholesterol circulating in the blood. The CD8⁺ Treg approach instead aims to alter immune-vascular communication inside the vessel wall.
The two strategies would not necessarily compete. If the approach eventually proves useful in humans, it could theoretically complement aggressive lipid lowering rather than replace it.
That distinction matters because established cardiovascular prevention still rests on controlling LDL cholesterol, blood pressure, smoking, diabetes and other major risk factors. Experimental immune therapies are nowhere near ready to replace those measures.
The findings help explain why CD8⁺ T cells have seemed contradictory in atherosclerosis
Previous studies have produced mixed results about whether CD8⁺ T cells worsen or protect against atherosclerosis.
The new work provides one possible explanation: CD8⁺ T cells are not a single functional group.
Effector CD8⁺ T cells can promote inflammatory damage, while a smaller regulatory subset may protect the artery wall. The net effect may depend on which population dominates at a particular stage of disease.
A 2026 review in Nature Reviews Cardiology similarly concluded that CD8⁺ T cells can have different, and sometimes opposing, roles across the course of atherosclerosis.
The study does not show that the approach prevents heart attacks or strokes
The biggest limitation is that the therapeutic experiments were performed in mice.
The researchers used human plaque single-cell data to identify relevant cell interactions, but they did not give the anti-CD8α antibody to people with coronary artery disease.
It is therefore unknown whether the same regulatory CD8⁺ T-cell population can be safely expanded in humans, whether doing so changes human plaque composition, or whether it reduces cardiovascular events.
There are also important safety questions. CD8⁺ T cells are essential for antiviral and antitumor immunity. Any therapy that changes their activation must avoid weakening immune surveillance.
Mouse plaques are useful models but not perfect copies of human plaques
Another limitation is the animal model itself.
The investigators modeled atherosclerosis in Apoe-deficient mice and in mice in which PCSK9 was increased using an adeno-associated viral approach. These are widely used systems for studying plaque biology, but mouse plaques differ from human plaques in important ways.
For example, spontaneous plaque rupture with the same clinical consequences seen in human coronary disease is uncommon in standard mouse models.
That means reductions in plaque area or improvements in plaque composition should be interpreted as mechanistic evidence, not direct proof that a therapy would prevent myocardial infarction or stroke.
The next step is to determine whether the same axis can be targeted safely in people
The study identifies a specific immune-vascular pathway that could be tested in future translational studies: the CD8⁺ Treg-Notch axis.
Researchers will need to establish whether the same protective CD8⁺ T-cell phenotype can be reliably identified in human blood or plaques, whether its abundance predicts cardiovascular risk, and whether it can be expanded without impairing normal immunity.
If those questions can be answered, the work could open a new direction in cardiovascular immunotherapy: not broadly suppressing inflammation, but shifting the immune system toward a protective state that keeps vascular smooth muscle cells stable.
The study points to a new way of thinking about plaque stability
The most important message is not that an antibody treatment for atherosclerosis is ready for patients. It is that immune cells may directly control whether vascular smooth muscle cells remain stable or switch into a disease-promoting state.
By showing that protective CD8⁺ regulatory T cells can restore Notch signaling and slow atherosclerosis in mice, the study adds a specific mechanism to the broader idea that cardiovascular disease is shaped by both metabolism and immunity.
For now, the findings are best viewed as a promising preclinical target that still requires substantial human validation.
References
- Gao W, Hou Y, Liu J, et al. Inducing CD8+ Tregs Limits Atherosclerosis via Notch-Mediated VSMC Quiescence. Circulation Research. 2026;139(9):e328918. DOI: 10.1161/CIRCRESAHA.126.328918.
- Tandon I, Yosri M, Soliman H, et al. CD8+ T cells in atherosclerosis and coronary artery disease. Nature Reviews Cardiology. 2026. DOI: 10.1038/s41569-026-01295-7.
- Chinese University of Hong Kong Faculty of Medicine. CUHK study identifies protective T cells as novel therapeutic target in atherosclerosis. October 11, 2026. CUHK research summary.